Lorenzo, I would like to start by questioning you on how to choose different treatment options for small renal masses.

Good morning, everybody, and thank you, Daniela, for the question.

Talking about treatments in localized renal mass, especially for small renal masses, nowadays is very complex because we know that we have a lot of treatment as alternative to surgery.

I mean, access surveillance or radiofrequency, creablation, microwave, but also radiation therapy.

So the key, of course, is the patient selection for surgical versus non-surgical treatment.

And in my opinion, the best way to plan the right approach is to consider tumor characteristics.

I mean, the size, the location, I mean, anterior or posterior mass, more suitable for percutaneous access or... surveillance, but also relation with a major vessel or collective systems.

And then I would like to move to another question, and this time I would like to challenge Lorenzo, because due to the limited diagnostic performance of conventional imaging and the limited access and diffusion of novel molecular functional imaging, like we discussed, the question is, what is the current role of renal cancer biomarkers?